Understanding needs of prostate cancer patients and caregivers during and after radiotherapy
Official title: Qualitative Erhebung Zur Erfassung Der Bedürfnisse Von Patienten Und Deren Angehörigen während Und Nach Einer Strahlentherapie Bei Prostatakarzinomerkrankung Und Deren Einstellung Und Wünsche bezüglich Einer Prähabilitationsmaßnahme
Run by Charite University, Berlin, Germany · NCT07156903 · Data updated 2026-11-12
We ask men receiving curative radiotherapy for prostate cancer and their caregivers about their experiences, needs, and what they'd want from prehabilitation before or during treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 60 (estimated) |
| Sponsor | Charite University, Berlin, Germany Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Berlin) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | October 31, 2026 |
| Study ends | November 30, 2026 |
| Registry record updated | September 5, 2025 |
| Trial ID | NCT07156903 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men aged 18 or older with prostate cancer scheduled for curative-intent radiotherapy who speak German and can consent are the ideal candidates, and relatives may also be invited to participate.
✕Probably not a fit
People not undergoing curative radiotherapy, those unable to participate in German-language interviews, or with impaired capacity to consent are unlikely to benefit directly from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a qualitative interview project at Charité Universitätsmedizin Berlin to gather experiences from prostate cancer patients undergoing curative-intent radiotherapy and, where possible, their relatives. Semi-structured interviews in German will explore treatment side effects, everyday challenges during and after radiotherapy, and attitudes toward starting supportive measures before or during therapy (prehabilitation). Responses will be analyzed qualitatively to identify common needs and preferences and to inform the design of a tailored prehabilitation program. Findings will be used to shape interventions aiming to reduce functional decline and improve quality of life during and after radiotherapy.
Why it matters
Potential benefit: If successful, this work could lead to prehabilitation programs started before or during radiotherapy that reduce severe side effects and improve patients' quality of life.
How similar studies have gone: Prehabilitation approaches have shown benefits in surgical oncology and some radiotherapy settings, but focused qualitative work and program development specifically for prostate radiotherapy remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed Prostate Cancer with curativ intended Radiotherapy * min. 18 years * sufficient knowledge of German language for participation in interviews * Capacity to consent Exclusion Criteria: * age \<18 years
Where it's running
-
Charité Universitätsmedizin Berlin
Berlin, Germany Recruiting
Study contacts
- Study coordinator: Franziska Hausmann, MD
- Email: franziska.hausmann@charite.de
- Phone: +4930 450 557000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Radiation therapy options for high-risk prostate cancer
This trial tests different ways of giving radiation therapy to see which balance best controls the cancer with the fewest side effects in men with high-risk, non-metastatic prostate cancer.
-
Post-treatment care program for breast and prostate cancer survivors
This program tests whether a focused questionnaire plus quality-of-life screening can detect and help manage side effects in people who have finished curative treatment for breast or prostate cancer.
-
DNA vaccine plus nivolumab and targeted radiation for recurrent oligometastatic prostate cancer
This study will try a DNA vaccine called pTVG-HP together with the checkpoint blocker nivolumab and targeted radiation to see if they can eliminate metastatic tumors in men with non-castrate, recurrent oligometastatic prostate cancer.
-
Testing different chemotherapy drugs plus surgery for prostate cancer patients without metastasis
This study is testing if giving different chemotherapy drugs before surgery can help men with localized prostate cancer control their tumors better and lower the chances of the cancer getting worse.
-
Simultaneous Integrated Boost Radiotherapy for High- and Very High-Risk Prostate Cancer
This study tests a hypofractionated SIB-VMAT radiotherapy approach to see if it safely treats the prostate and pelvic lymph nodes in high-risk prostate cancer patients over 20 fractions.
-
Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria
This project collects medical and treatment information to see how prostate cancer is diagnosed and managed in Algerian men with confirmed disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.